Dose-Response Curve Visualizer

Visualize how drug effect changes with concentration using the Hill equation: E = Emax × [C]^n / (EC50^n + [C]^n). Adjust EC50 (potency), Emax (efficacy), and Hill coefficient (cooperativity) to see how these parameters shape the sigmoidal dose-response relationship fundamental to pharmacology.

EC50 (nM)

Half-maximal effective concentration

Emax (%)

Maximum effect

Hill Coefficient (n)

n=1: simple binding, n>1: cooperative

Dose-Response Curve (Hill Equation)

Response (%Emax) log[Concentration]

50%

E = × [C] / ( + [C])

Dose-Response Relationships in Pharmacology

The dose-response relationship describes how the magnitude of a drug's effect changes as a function of dose or concentration. Most dose-response curves follow a sigmoidal (S-shaped) pattern when plotted on a logarithmic concentration axis. The Hill equation — E = Emax × [C]ⁿ / (EC50ⁿ + [C]ⁿ) — mathematically models this relationship using three parameters: Emax (maximum effect), EC50 (half-maximal effective concentration), and the Hill coefficient n (slope factor). These parameters are extracted from concentration-response experiments and underpin dose selection in drug development.

EC50 is a measure of drug potency — a lower EC50 means greater potency because less drug is needed to produce half the maximum effect. Emax reflects drug efficacy, the intrinsic ability to produce a biological response regardless of dose. Two drugs can have identical EC50 values but different Emax values, making one a full agonist and the other a partial agonist at a given receptor. The Hill coefficient n describes curve steepness: n = 1 corresponds to simple one-site binding, n > 1 indicates positive cooperativity (the curve is steeper), and n < 1 suggests negative cooperativity or multiple binding sites with different affinities.

The therapeutic index (TI) is the ratio of the dose producing toxicity (TD50) to the dose producing the desired effect (ED50). A wide TI — as seen with penicillin antibiotics — allows for large dosing margins, while a narrow TI — as with warfarin, digoxin, or lithium — demands careful dose titration and therapeutic drug monitoring. Understanding dose-response relationships also informs the concept of the maximum tolerated dose (MTD) in oncology, where the therapeutic window between efficacy and toxicity can be extremely narrow.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

How to Use

1
Enter dose-response parameters
Input the maximum effect (Emax), the dose producing 50% of maximum effect (EC50), and the Hill coefficient (n, also called the slope factor or cooperativity coefficient) for the drug-receptor system of interest. These parameters are derived from concentration-response experiments and published in pharmacology literature.
2
Generate dose-response curve
The visualizer plots the sigmoidal Hill equation E = Emax × Cⁿ / (EC50ⁿ + Cⁿ) across a log-dose range spanning 3–4 orders of magnitude below and above EC50. Log-linear concentration axes are standard in pharmacology to linearize the sigmoidal curve and facilitate comparison of EC50 values across compounds.
3
Compare agonist and antagonist curves
Add competitive or non-competitive antagonist parameters to visualize rightward shifts in EC50 (competitive antagonism, Schild analysis) or depression of Emax (non-competitive antagonism). The tool calculates the pA2 value for competitive antagonists from Schild plots, a quantitative measure of antagonist potency.

About

The dose-response relationship is the foundational principle of pharmacology, capturing the quantitative relationship between drug concentration and biological effect across a continuum from no effect to maximum response. Pharmacologist John Gaddum and the Clark occupancy theory in the 1930s established the mathematical framework now encoded in the Hill equation, which describes how graded concentration increases produce sigmoidal response curves when plotted on a log-concentration axis. This mathematical framework has been extended to characterize competitive and non-competitive antagonism through Schild analysis, partial agonism through intrinsic efficacy parameters, and allosteric modulation through operational models of agonism.

Modern quantitative pharmacology, integrating in vitro concentration-response data with in vivo pharmacokinetic modeling, enables mechanism-based translation from cellular assays to animal models to human clinical predictions. PK-PD modeling relates plasma drug concentrations over time (pharmacokinetic compartment model) to time-course of effect (pharmacodynamic sigmoidal Emax model), producing integrated simulations of drug action that support dose selection in clinical development. The FDA uses PK-PD modeling and simulation (M&S) as part of regulatory submissions to justify dosing regimens in special populations, support extrapolation from adult to pediatric doses, and characterize dose-response relationships for labeling without empirical dose-ranging studies when data from existing trials support model extrapolation.

This dose-response visualizer implements the Hill equation and Schild equation to create interactive concentration-effect curves supporting pharmacology education and comparative analysis of drug potency, efficacy, and antagonism. By enabling visualization of how Emax, EC50, and Hill coefficient independently govern curve shape, position, and steepness, the tool builds quantitative pharmacological intuition applicable across drug classes, target types, and experimental contexts.

FAQ

What is the Hill equation and how does the Hill coefficient affect curve shape?

The Hill equation, E = Emax × Cⁿ / (EC50ⁿ + Cⁿ), describes sigmoidal dose-response relationships where n is the Hill coefficient governing the steepness of the transition from minimum to maximum effect. A Hill coefficient of 1 produces a classic hyperbolic (Langmuir) curve occupying 2 log units between 10% and 90% of maximum effect. Hill coefficients greater than 1 indicate positive cooperativity (steeper sigmoidal curve, narrower dynamic range), characteristic of ligand-gated ion channels and allosteric enzyme systems. Hill coefficients less than 1 indicate negative cooperativity or receptor heterogeneity. The Hill equation is an empirical descriptor; mechanistic interpretation of the Hill coefficient as the number of binding sites requires caution.

What is the difference between EC50 and IC50?

EC50 is the concentration of an agonist producing 50% of its maximum stimulatory effect, used to characterize agonist potency in activation assays. IC50 is the concentration of an inhibitor producing 50% inhibition of a baseline response (an enzyme activity, receptor activation level, or cell growth), used to characterize inhibitor potency. IC50 values are assay-dependent and vary with substrate concentration; for competitive inhibitors, the Cheng-Prusoff equation converts IC50 to the intrinsic inhibition constant Ki (Ki = IC50 / (1 + [S] / Km)), which is assay-independent. In drug discovery, IC50 or Ki is used for potency ranking during lead optimization, while Ki is preferred for structure-activity relationship analysis.

How does a competitive antagonist shift the dose-response curve?

A competitive antagonist binds reversibly to the same receptor site as the agonist, reducing the probability of agonist occupancy in a concentration-dependent manner. At increasing antagonist concentrations, the agonist dose-response curve shifts parallel to the right (higher EC50 required to achieve the same effect), but Emax is preserved because increasing agonist concentrations can displace the antagonist. The dose ratio (DR = EC50 with antagonist / EC50 without antagonist) increases linearly with antagonist concentration, producing a linear Schild plot. The slope of the Schild plot should equal 1 for a pure competitive antagonist, and the x-intercept gives pA2 = -log(KB) where KB is the equilibrium dissociation constant for the antagonist.

What is the therapeutic window in the context of dose-response?

The therapeutic window is the dose range between the minimum effective dose (ED50 or EC50 for the desired effect) and the minimum toxic dose (TD50 or TC50 for the adverse effect). The ratio of TD50 to ED50 defines the therapeutic index — a quantitative measure of dosing latitude. Drugs with overlapping dose-response curves for efficacy and toxicity have narrow therapeutic indices requiring precise dosing and patient monitoring. Dose-response visualization of both therapeutic and toxicity curves on the same graph illustrates the clinical challenge and supports rational design of dosing regimens that maximize efficacy while minimizing toxicity probability.

How are dose-response curves used in drug discovery?

Dose-response curves are the primary analytical tool in drug discovery for quantifying compound potency and establishing structure-activity relationships (SAR). High-throughput screening campaigns determine IC50 or EC50 for thousands of compounds against a biological target, enabling potency ranking and identification of chemotypes for optimization. Lead optimization tracks SAR by examining how structural modifications change EC50, Emax, Hill coefficient, and selectivity against related targets. In vitro pharmacology assessments in discovery typically use radioligand binding (Kd), functional activation assays (EC50), and reporter gene assays. These parameters inform in vitro to in vivo pharmacokinetic-pharmacodynamic (PK-PD) modeling to predict efficacious doses in preclinical species and, ultimately, first-in-human dose selection.